Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
- PMID: 30829432
- DOI: 10.1111/liv.14085
Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Abstract
The complexity of cholangiocarcinoma (CCA) cellularity and the molecular perturbation mechanisms that underlie the diversity of growth patterns of this malignancy remain a clinical concern. Tumours of the biliary system display significant intrinsic chemoresistance, caused by significant stromal involvement and genome-wide tumour heterogeneity, hampering disease remission and palliation as well as promoting the metastatic behaviour. It is crucial to advance our present understanding of the risk and molecular pathogenesis of CCA. This will facilitate the delineation of patient subsets based on molecular perturbations and adjust for precision therapies.
Keywords: cholangiocarcinoma; metastasis; precision therapy.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma.Surg Pathol Clin. 2022 Sep;15(3):529-539. doi: 10.1016/j.path.2022.05.006. Epub 2022 Aug 2. Surg Pathol Clin. 2022. PMID: 36049834 Review.
-
Highlights of topic "Biochemical and molecular pathological aspects of cholangiocarcinoma".J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):359-61. doi: 10.1002/jhbp.91. J Hepatobiliary Pancreat Sci. 2014. PMID: 24840727 No abstract available.
-
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.Curr Opin Gastroenterol. 2015 May;31(3):264-8. doi: 10.1097/MOG.0000000000000171. Curr Opin Gastroenterol. 2015. PMID: 25763789 Free PMC article. Review.
-
Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond.Semin Liver Dis. 2023 May;43(2):218-225. doi: 10.1055/a-2049-3149. Epub 2023 Mar 7. Semin Liver Dis. 2023. PMID: 36882151 Review.
-
Cholangiocarcinoma: molecular pathways and therapeutic opportunities.Semin Liver Dis. 2014 Nov;34(4):456-64. doi: 10.1055/s-0034-1394144. Epub 2014 Nov 4. Semin Liver Dis. 2014. PMID: 25369307 Free PMC article. Review.
Cited by
-
PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.Gut. 2024 Sep 9;73(10):1712-1724. doi: 10.1136/gutjnl-2023-331237. Gut. 2024. PMID: 38857989 Free PMC article.
-
Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinoma.JHEP Rep. 2025 Apr 3;7(7):101416. doi: 10.1016/j.jhepr.2025.101416. eCollection 2025 Jul. JHEP Rep. 2025. PMID: 40529213 Free PMC article.
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer.Br J Cancer. 2020 Sep;123(7):1047-1059. doi: 10.1038/s41416-020-0987-3. Epub 2020 Jul 22. Br J Cancer. 2020. PMID: 32694694 Free PMC article. Review.
-
Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures.Therap Adv Gastroenterol. 2021 Apr 15;14:17562848211002023. doi: 10.1177/17562848211002023. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 33948111 Free PMC article. Review.
-
From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification.Gut. 2023 Nov;72(11):2149-2163. doi: 10.1136/gutjnl-2023-330461. Epub 2023 Aug 7. Gut. 2023. PMID: 37549980 Free PMC article.
